Cost Plus Drugs Eyes Custom Rare-Disease Medicines — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mark Cuban has a new vision for Cost Plus Drugs to shake up the business of custom-made rare-disease medicines.
- Cost Plus Drugs began by buying generic drugs, sidestepping pharmacy benefit managers and reselling them at a 15% markup.
- Cost Plus Drugs’ plant can quickly pivot between small batches of different drugs, Cuban and CEO Alex Oshmyansky said.
- Alex Oshmyansky said the flexible production could be useful for making experimental treatments for individuals or tiny groups of patients.
Why it matters: The pitch is tailored to individuals and tiny patient groups because Cost Plus Drugs’ plant can switch among small drug batches for experimental treatments. Its original model of reselling generic drugs at a 15% markup is no longer the whole proposition; Cuban is presenting the company as a custom manufacturer.
Ask SkimNews
